A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors

被引：1
|
作者：
Davis, S. Lindsey [1 ]
Lam, Elaine T. [1 ]
Corr, Bradley R. [1 ]
O'Bryant, Cindy L. [1 ]
Glode, Ashley [1 ]
Adler, Nichole [1 ]
Pitts, Todd M. [1 ]
Tentler, John J. [1 ]
Capasso, Anna [1 ]
Dailey, Kyrie [1 ]
Serkova, Natalie J. [1 ]
Weekes, Colin D. [2 ]
Gustafson, Daniel L. [3 ]
Lieu, Christopher H. [1 ]
Messersmith, Wells A. [1 ]
Leong, Stephen [1 ]
Eckhardt, S. Gail [4 ]
Diamond, Jennifer R. [1 ]
机构：
[1] Univ Colorado, Denver, CO 80202 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Colorado State Univ, Ft Collins, CO 80523 USA
[4] Univ Texas Austin, Austin, TX 78712 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A083
引用
收藏
页数：2
相关论文
共 50 条
  • [21] TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
    Howard A. Burris
    C. D. Kurkjian
    L. Hart
    S. Pant
    P. B. Murphy
    S. F. Jones
    R. Neuwirth
    C. G. Patel
    F. Zohren
    J. R. Infante
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 261 - 273
  • [22] TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
    Burris, Howard A., III
    Kurkjian, C. D.
    Hart, L.
    Pant, S.
    Murphy, P. B.
    Jones, S. F.
    Neuwirth, R.
    Patel, C. G.
    Zohren, F.
    Infante, J. R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (02) : 261 - 273
  • [23] PHASE 1 STUDY OF MLN8237 (ALISERTIB) IN ADULT EAST ASIAN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
    Kim, W. S.
    Venkatakrishnan, K.
    Kim, T. M.
    Lin, C. -C.
    Thye, L. S.
    Chng, W. J.
    Ma, B.
    Chen, M. -H.
    Liu, H.
    Benaim, E.
    ANNALS OF ONCOLOGY, 2013, 24
  • [24] Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
    Venkatakrishnan, Karthik
    Kim, Tae Min
    Lin, Chia-Chi
    Thye, Lim Soon
    Chng, Wee Joo
    Ma, Brigette
    Chen, Ming Huang
    Zhou, Xiaofei
    Liu, Hua
    Kelly, Virginia
    Kim, Won Seog
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 942 - 953
  • [25] Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)-An Investigational Aurora A Kinase Inhibitor-in Patients with Advanced Hematologic Malignancies
    Kelly, Kevin R.
    Padmanabhan, Swaminathan
    Goy, Andre
    Berdeja, Jesus G.
    Reeder, Craig B.
    McDonagh, Kevin T.
    Zhou, Xiaofei
    Danaee, Hadi
    Xiao, Hugh
    Benaim, Ely
    Shea, Thomas C.
    BLOOD, 2011, 118 (21) : 1061 - 1062
  • [26] Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
    Karthik Venkatakrishnan
    Tae Min Kim
    Chia-Chi Lin
    Lim Soon Thye
    Wee Joo Chng
    Brigette Ma
    Ming Huang Chen
    Xiaofei Zhou
    Hua Liu
    Virginia Kelly
    Won Seog Kim
    Investigational New Drugs, 2015, 33 : 942 - 953
  • [27] A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors
    Davis, S. Lindsey
    Messersmith, Wells A.
    Purcell, W. Thomas
    Lam, Elaine T.
    Corr, Bradley R.
    Leal, Alexis D.
    Lieu, Christopher H.
    O'Bryant, Cindy L.
    Smoots, Stephen G.
    Dus, Evan D.
    Jordan, Kimberly R.
    Serkova, Natalie J.
    Pitts, Todd M.
    Diamond, Jennifer R.
    CANCERS, 2024, 16 (08)
  • [28] Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies
    Padmanabhan, Swaminathan
    Shea, Thomas C.
    Vose, Julie M.
    Reeder, Craig B.
    Berdeja, Jesus G.
    McDonagh, Kevin T.
    Goy, Andre
    Kelly, Kevin R.
    Zhou, Xiaofei
    Liu, Hua
    Fingert, Howard
    Fowler, Nathan
    BLOOD, 2010, 116 (21) : 1154 - 1154
  • [29] Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Cervantes, Andres
    Elez, Elena
    Roda, Desamparados
    Ecsedy, Jeffrey
    Macarulla, Teresa
    Venkatakrishnan, Karthik
    Rosello, Susana
    Andreu, Jordi
    Jung, JungAh
    Sanchis-Garcia, Juan Manuel
    Piera, Adelaida
    Blasco, Inma
    Manos, Laura
    Perez-Fidalgo, Jose-Alejandro
    Fingert, Howard
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4764 - 4774
  • [30] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumors
    Dees, E. C.
    Infante, J. R.
    Burris, H. A.
    Astsaturov, I. A.
    Stinchcombe, T.
    Liu, H.
    Galvin, K.
    Venkatakrishnan, K.
    Fingert, H. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345